Gene

LRP1B

LDL receptor related protein 1B

Explore in graph →CI-GENE-00010494HGNC:6693 ENSG00000168702 NCBI 53353 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
LRP1B Deletion1
(prognostic)	GlioblastomaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Classical Hodgkins Lymphoma (SCCC, Blood Cancer Discov 2023) chl_sccc_2023	Classic Hodgkin Lymphoma	Ssm

Literature

Linked publications (4)

25 per page, newest first.

pubmedPublishedShowing 1–4 of 4 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

LRP1B deletion is associated with poor outcome for glioblastoma patients.
· J Neurol Sci · 2015 · PMID 26428308 · validated civic_curation pubmed
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
· J Immunother Cancer · 2021 · PMID 33653800 · validated civic_curation pubmed
LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
· Transl Lung Cancer Res · 2023 · PMID 37057124 · validated civic_curation pubmed
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.
· Cancer Res · 2012 · PMID 22896685 · validated

LRP1B Exon 12-22 Deletion1
Doxorubicin	Malignant Ovarian Neoplasm	Predictive	D	Supports Resistance	3	accepted	EID679 A minimum common region of deletion of 0.19Mb, encompassing exons 12–22 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance. Transfection of mLRP1B4, a fully functional minig… (full text at CIViC) PMID 22896685 · Cowin et al., 2012 · Open in CIViC	civic

LRP1B Exon 12-22 Deletion1

Doxorubicin

Malignant Ovarian Neoplasm

Predictive

Supports Resistance

accepted

EID679

A minimum common region of deletion of 0.19Mb, encompassing exons 12–22 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance. Transfection of mLRP1B4, a fully functional minig… (full text at CIViC)

PMID 22896685 · Cowin et al., 2012 · Open in CIViC

civic

LRP1B Loss-of-function2
Immune Checkpoint Inhibitor	Solid NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID12252 In this trial, 101 patients with solid tumours, including lung, prostate, sarcoma, melanoma, and breast cancer, harbouring LRP1B alterations were treated with immune checkpoint inhibitors. Most patien… (full text at CIViC) PMID 33653800 · Brown et al., 2021 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID12652 In a retrospective LUAD cohort treated with PD-1 plus CTLA-4 blockade (n = 59; LRP1B-MT n = 15, LRP1B-WT n = 44), LRP1B-mutated tumors showed significantly longer PFS (log-rank p = 0.0016), along with… (full text at CIViC) PMID 37057124 · He et al., 2023 · Open in CIViC	civic

LRP1B Loss-of-function2

Immune Checkpoint Inhibitor

Solid NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID12252

In this trial, 101 patients with solid tumours, including lung, prostate, sarcoma, melanoma, and breast cancer, harbouring LRP1B alterations were treated with immune checkpoint inhibitors. Most patien… (full text at CIViC)

PMID 33653800 · Brown et al., 2021 · Open in CIViC

civic

〃

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID12652

In a retrospective LUAD cohort treated with PD-1 plus CTLA-4 blockade (n = 59; LRP1B-MT n = 15, LRP1B-WT n = 44), LRP1B-mutated tumors showed significantly longer PFS (log-rank p = 0.0016), along with… (full text at CIViC)

PMID 37057124 · He et al., 2023 · Open in CIViC

civic